Accuray Incorporated (ARAY)vsDexCom Inc (DXCM)
ARAY
Accuray Incorporated
$0.28
-3.35%
HEALTHCARE · Cap: $37.17M
DXCM
DexCom Inc
$90.80
+1.42%
HEALTHCARE · Cap: $31.49B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 1059% more annual revenue ($4.97B vs $428.57M). DXCM leads profitability with a 20.1% profit margin vs -10.8%. DXCM appears more attractively valued with a PEG of 1.56. DXCM earns a higher WallStSmart Score of 72/100 (B).
ARAY
Hold37
out of 100
Grade: F
DXCM
Strong Buy72
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -110.6% — below average capital efficiency
Revenue declined 7.4%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 13.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARAY
The strongest argument for ARAY centers on Price/Book.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : ARAY
The primary concerns for ARAY are Market Cap, PEG Ratio, Return on Equity. Debt-to-equity of 4.37 is elevated, increasing financial risk.
Bear Case : DXCM
The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
ARAY profiles as a turnaround stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 37/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Accuray Incorporated
HEALTHCARE · MEDICAL DEVICES · USA
Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?